LIU, HAO LI,刘浩澧,劉浩澧,CHU, PO CHUN,朱伯骏,朱伯駿,CHANG, TING KUANG,昌廷光,昌廷光,WEI, KUO CHEN,魏国珍,魏國珍,CHEN, PING YUAN,陈品元,陳品元,HUANG, CHIUNG YIN,黄琼莹,黃瓊瑩
申请号：
TW105136606
公开号：
TW201729866A
申请日:
2016.11.10
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
The present invention relates to a method for reducing an effective amount of Bevacizumab required for treating brain tumor. The present invention also provides a kit used for the aforesaid method. The present method adopts a combination strategy to combine Bevacizumab treatment with ultrasound exposure, which comprises at least the following steps: administering Bevacizumab to a subject administering an ultrasound-response medium to said subject and administering said subject with an ultrasound exposure. Specific effective amount of the Bevacizumab treatment and the ultrasound exposure were identified. The efficacy of conventional Bevacizumab treatment is significantly improved.本發明係關於一種減少治療腦瘤所需之貝伐單抗有效用量之方法。本發明亦提供一種用於前述方法之套組。該方法以結合貝伐單抗療法與超音波照射為策略,包含實施至少以下步驟:施用貝伐單抗予一受試對象;施用一超音波響應介質於該受試對象;以及施用一超音波照射於該受試對象。實驗測定出貝伐單抗與超音波照射之精確有效用量,傳統貝伐單抗療法之效能亦因此顯著提升。
